Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of “Hold” from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been assigned a consensus recommendation of “Hold” from the nine ratings firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $8.63.

A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FULC. BNP Paribas Financial Markets bought a new position in Fulcrum Therapeutics during the fourth quarter worth about $38,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Fulcrum Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after acquiring an additional 4,701 shares during the period. Walleye Capital LLC acquired a new position in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $59,000. Intech Investment Management LLC bought a new stake in Fulcrum Therapeutics in the 3rd quarter valued at $62,000. Finally, Mariner LLC acquired a new stake in Fulcrum Therapeutics during the 4th quarter valued at $78,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Down 0.9 %

Shares of NASDAQ:FULC opened at $3.22 on Friday. The firm has a market cap of $173.81 million, a price-to-earnings ratio of -10.39 and a beta of 2.20. Fulcrum Therapeutics has a 12 month low of $2.86 and a 12 month high of $12.40. The company’s fifty day simple moving average is $3.99 and its 200 day simple moving average is $4.40.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). Research analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current fiscal year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.